


## Ophthalmic Images

## Presumed Autoimmune Pigmented Paravenous Retinochoroidal Atrophy in a Female Patient Aged 69 Years

Celso Costa, MD, MSc; João Pedro Marques, MD, MSc



**Figure.** Presumed autoimmune pigmented paravenous retinochoroidal atrophy. Ultra-widefield fundus autofluorescence of the right (A) and left (B) eyes demonstrating bilateral and symmetrical hypoautofluorescence along the paravenous regions, with areas of isoautofluorescence between them. Patchy clumps of decreased fundus autofluorescence signal were identified in the macula, indicating macular atrophy. Macular-focused images are displayed in insets.

**A 69-year-old White female** with rheumatoid arthritis and scleroderma presented with long-standing and slowly progressive vision loss and nyctalopia. Family history was negative. At examination, visual acuity was hand motions bilaterally. Results of anterior-segment biomicroscopy were unremarkable. Ophthalmoscopy revealed bilateral optic disc pallor, vessel thinning, and retinochoroidal atrophy along the retinal vessels. Pigment clumping was evident in the atrophic areas. Macular atrophy was present bilaterally.



CME at [jamacmelookup.com](http://jamacmelookup.com)

On ultra-widefield fundus autofluorescence (FAF), patchy clumps of decreased FAF signal were identified in the atrophic areas (Figure). No clinically relevant variants were found on panel genetic testing. Pigmented paravenous retinochoroidal atrophy (PPRCA) is a rare disease of unknown etiology, although dysgenetic, degenerative, hereditary, and inflammatory causes have been suggested. It is usually slowly progressive, and visual acuity remains good unless the macula is involved.<sup>1,2</sup> Given the personal history of autoimmune disease and a negative genetic test result, a diagnosis of presumed autoimmune PPRCA was suggested.

## ARTICLE INFORMATION

**Author Affiliations:** Ophthalmology Unit, Centro de Responsabilidade Integrada de Oftalmologia, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal (Costa, Marques); University Clinic of Ophthalmology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal (Marques); Clinical Academic Center of Coimbra, Coimbra, Portugal (Marques).

**Corresponding Author:** Celso Costa, MD, MSc, Ophthalmology Unit, Centro de Responsabilidade

Integrada de Oftalmologia, Centro Hospitalar e Universitário de Coimbra, Praceta Professor Mota Pinto, 3004-561 Coimbra, Portugal ([celsomiguelcosta@hotmail.com](mailto:celsomiguelcosta@hotmail.com)).

**Conflict of Interest Disclosures:** Dr Marques reported receiving personal fees from Novartis and Bayer and grants from the Portuguese Society of Ophthalmology outside the submitted work. No other disclosures were reported.

**Additional Contributions:** We thank the patient for granting permission to publish this information.

## REFERENCES

1. Jung I, Lee Y, Kang S, Won J. Pigmented paravenous retinochoroidal atrophy: a case report supported by multimodal imaging studies. *Medicina (Kaunas)*. 2021;57(12):1382. doi:10.3390/medicina57121382
2. Sun Y, Li J, Yu L, Zheng Y. Pigmented paravenous retinochoroidal atrophy with acute angle-closure glaucoma and posterior subcapsular cataract: a case report. *BMC Ophthalmol*. 2022;22(1):184. doi:10.1186/s12886-022-02355-5